Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Endocrine 2

Conditions

Prostatic Neoplasms 1641Carcinoma, Renal Cell 504Urinary Bladder Neoplasms 462Carcinoma, Transitional Cell 234Breast Neoplasms 228Kidney Neoplasms 217Neoplasms 194Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 172Ovarian Neoplasms 163Melanoma 162Neoplasm Metastasis 143Lung Neoplasms 128Non-Muscle Invasive Bladder Neoplasms 107Pancreatic Neoplasms 103Stomach Neoplasms 101Uterine Cervical Neoplasms 93Squamous Cell Carcinoma of Head and Neck 86Endometrial Neoplasms 84Carcinoma, Hepatocellular 77Sarcoma 75Esophageal Neoplasms 72Head and Neck Neoplasms 70Triple Negative Breast Neoplasms 67Adenocarcinoma 66Colonic Neoplasms 53Testicular Neoplasms 52Disease 47Urologic Neoplasms 46Wilms Tumor 45

Interventions

AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroendocrine Prostate Cancer × Genitourinary × 1 year × Clear all
NCT04702737 2025-09-12

DeLLpro-300

Amgen

Phase 1 Completed
41 enrolled 19 charts
EndocrineGenitourinary

Neuroendocrine Prostate Cancer

NCT07024277 2025-06-17

Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Not yet recruiting
60 enrolled
EndocrineGenitourinary

Neuroendocrine Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡